All In Biotech

NDA 216190 · Fidelity Biopharma

Ontralfy

Tizanidine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Dec 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Dec 12, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

46

9 Phase 3, 5 recruiting

FAERS reports

7,084

3,950 serious, 419 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 25, 2025.

Ontralfy is indicated for the treatment of spasticity in adults. Ontralfy is a central alpha-2-adrenergic agonist indicated for the treatment of spasticity in adults. ( 1 )

Mechanism: Tizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ONTRALFY · TIZANIDINE HYDROCHLORIDE EQ 2MG BASE/5ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tizanidine" as an intervention, any sponsor and status, largest first.

All 46 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue629
  • headache589
  • nausea518
  • pain497
  • drug ineffective484
  • product dose omission issue462
  • somnolence375
  • diarrhoea366
  • dyspnoea356
  • fall342
  • arthralgia334
  • dizziness334

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200443
200527
200637
20073
200848
200947
201035
201181
2012151
201367
201499
2015148
2016221
2017194
2018224
2019294
2020434
2021470
2022862
2023862
2024957
20251,009
2026771

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 138 on PubMed

Sponsor: Fidelity Biopharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.